ENTA · Enanta Pharmaceuticals Inc
$13.13
-0.38 (-2.81%)
At close · Aug 20
Market Cap
$393.34M
Shares
29.13M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.13
Open$13.42
Day$12.93–13.50
52W close$7.17–16.85
Avg vol 30d169K
Short int2.6M · 8.9% float · 17.7d
Short vol50%
Last earningsNov 25, 2024
DataJan 2020–Aug 2026
Filing10-Q · Aug 12
Up next
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−3%
below
Price vs 50-day avg
−1%
below
RSI (14)
48
neutral
MACD trend
Positive
52-week position
62%
mid-range
Momentum
relative strength
1-month return
+1%
trailing
6-month return
−8%
trailing
YTD return
−17%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $13 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +13 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.88% of float · ▲ +6.0% MoM · 17.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
121 holders — mid 3-yr range
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+16%
Y/Y
EPS growth
+30%
Y/Y
Free cash flow
$-32.2M
Balance sheet
$30.3M
net cash
Quant / Vol
risk profile
Volatility
108%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2024
Research and development expense
· fiscal year 2024
$125M – $145M
General and administrative expense
· fiscal year 2024
$50M – $60M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−3%
Neutral
Price vs 50-day avg
−1%
Neutral
RSI (14)
48
Neutral
MACD trend
Positive
Bullish
52-week position
62%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $13 › 200d $13 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +13 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.88% of float · ▲ +6.0% MoM · 17.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
121 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7
Now $13 · 62%
Range high $17
vs 200-day avg -3%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENTA
this stock
Enanta Pharmaceuticals Inc
|
$393.34M | -16.7% | +16.5% | — | 8.9% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENTA | -2.3% | +1.4% | -8.2% | +4.2% | -16.7% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -0.4% | -1.9% | -19.4% | +2.1% | -28.6% |
Key facts
CIK
1177648
CUSIP
29251M106
13F (30d)
135 filings
112 filers
Visit website
Investor relations